Cite
HARVARD Citation
Baselga, J. et al. (n.d.). Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology. 18 (7), pp. 904-916. [Online].